Dashboard
Manage Tickers

AVTEAerovate Therapeutics, Inc.

Nasdaq aerovatetx.com


$ 20.27 $ -0.46 (-2.22 %)    

Friday, 03-May-2024 15:52:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 20.29
$ 21.57
$ 0.00 x 0
$ 0.00 x 0
$ 20.08 - $ 21.65
$ 9.41 - $ 32.42
99,949
na
534.27M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-25-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ermenegildo-zegna-reports-fy23-results-joins-altice-usa-herbalife-and-other-big-stocks-moving-lower-on-friday
Ermenegildo Zegna Reports FY23 Results, Jo...
04/05/2024 14:27:21

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE:...

wells-fargo-maintains-overweight-on-aerovate-therapeutics-maintains-35-price-target
Wells Fargo Maintains Overweight on Aerova...
04/01/2024 16:07:11

Wells Fargo analyst Tiago Fauth maintains Aerovate Therapeutics (NASDAQ:AVTE) with a Overweight and maintains $35 price target.

aerovate-therapeutics-to-present-patient-baseline-characteristics-of-the-phase-2b-portion-of-the-phase-2bphase-3-impahct-trial-at-the-american-thoracic-society-2024-international-conference
Aerovate Therapeutics To Present Patient B...
03/27/2024 13:28:07

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve ...

recap-aerovate-therapeutics-q4-earnings
Recap: Aerovate Therapeutics Q4 Earnings
03/25/2024 21:20:05

aerovate-therapeutics-expects-cash-cash-equivalents-and-available-for-sale-investments-sufficient-to-fund-operations-into-2026-based-on-current-operating-plan
Aerovate Therapeutics Expects Cash, Cash E...
03/25/2024 20:16:30

aerovate-therapeutics-q4-2023-gaap-eps-074-misses-070-estimate
Aerovate Therapeutics Q4 2023 GAAP EPS $(0...
03/25/2024 20:15:29

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate ...

jefferies-assumes-aerovate-therapeutics-at-buy-raises-price-target-to-65
Jefferies Assumes Aerovate Therapeutics at...
03/25/2024 12:39:30

Jefferies analyst Eun Yang assumes Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and raises Price Target to $65.

aerovate-therapeutics-board-of-directors-appoints-habib-dable-as-board-chair
Aerovate Therapeutics Board Of Directors A...
03/06/2024 13:11:15

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve ...

aerovate-reports-simultaneous-completion-of-enrollment-in-phase-2b-portion-and-enrollment-of-first-patient-into-phase-3-in-impahct-trial-evaluating-av-101-topline-phase-2b-data-expected-in-june-2024
Aerovate Reports Simultaneous Completion O...
11/20/2023 21:47:22

aerovate-therapeutics-q3-eps-071-misses-069-estimate-cash-cash-equivalents-and-available-for-sale-securities-of-1352m-will-be-sufficient-to-fund-operations-into-2026
Aerovate Therapeutics Q3 EPS $(0.71) Misse...
11/13/2023 13:28:09

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate ...

recap-aerovate-therapeutics-q3-earnings
Recap: Aerovate Therapeutics Q3 Earnings
11/13/2023 13:25:11

stocks-that-hit-52-week-lows-on-thursday
Stocks That Hit 52-Week Lows On Thursday
09/21/2023 16:08:37

  During the session on Thursday, 461 stocks hit new 52-week lows.

stocks-that-hit-52-week-lows-on-friday
Stocks That Hit 52-Week Lows On Friday
09/15/2023 15:52:24

  Friday's session saw 169 companies set new 52-week lows.

stocks-that-hit-52-week-lows-on-monday
Stocks That Hit 52-Week Lows On Monday
09/11/2023 17:38:28

  Monday's session saw 175 companies set new 52-week lows.

stocks-that-hit-52-week-lows-on-friday
Stocks That Hit 52-Week Lows On Friday
09/08/2023 17:58:01

  Friday's session saw 225 companies set new 52-week lows.

aerovate-therapeutics-q2-eps-076-misses-070-estimate
Aerovate Therapeutics Q2 EPS $(0.76) Misse...
08/14/2023 12:31:11

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate ...

aerovate-therapeutics-presents-nonclinical-pharmacokinetic-data-in-support-of-av-101-a-novel-dry-powder-inhaled-formulation-of-imatinib-at-the-american-thoracic-society-2023-international-conference
Aerovate Therapeutics Presents Nonclinical...
05/22/2023 17:29:46

Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV d...

aerovate-therapeutics-inc-q1-eps-067-misses-060-estimate
Aerovate Therapeutics, Inc. Q1 EPS $(0.67)...
05/16/2023 04:12:47

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate ...

recap-aerovate-therapeutics-q1-earnings
Recap: Aerovate Therapeutics Q1 Earnings
05/15/2023 21:38:01

aerovate-therapeutics-says-entered-into-at-the-market-equity-offering-sales-agreement-with-bofa-securities-under-which-co-may-offer-sell-of-up-to-75m-in-common-shares
Aerovate Therapeutics Says Entered Into At...
04/05/2023 20:44:19

-SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION